Alpine Immune Sciences (ALPN) Releases Earnings Results, Misses Estimates By $0.31 EPS

Alpine Immune Sciences (NASDAQ:ALPN) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.31), Zacks reports. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 26.00%.

Shares of NASDAQ:ALPN traded up $0.03 during trading on Friday, reaching $4.84. The stock had a trading volume of 9,808 shares, compared to its average volume of 15,525. The company has a debt-to-equity ratio of 0.05, a current ratio of 20.99 and a quick ratio of 20.99. The firm has a market cap of $65.91 million, a PE ratio of -4.03 and a beta of 0.94. Alpine Immune Sciences has a fifty-two week low of $4.61 and a fifty-two week high of $11.75.

A number of equities analysts have recently weighed in on ALPN shares. Zacks Investment Research raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 25th. ValuEngine raised shares of Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 26th. Raymond James started coverage on shares of Alpine Immune Sciences in a research report on Monday, August 13th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Piper Jaffray Companies started coverage on shares of Alpine Immune Sciences in a research report on Thursday, September 27th. They issued an “overweight” rating and a $12.00 price objective for the company. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $12.67.

COPYRIGHT VIOLATION WARNING: “Alpine Immune Sciences (ALPN) Releases Earnings Results, Misses Estimates By $0.31 EPS” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://sportsperspectives.com/2018/11/09/alpine-immune-sciences-alpn-releases-earnings-results-misses-estimates-by-0-31-eps.html.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

See Also: Price to Earnings Ratio (PE) Basics

Earnings History for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply